Arbutus Biopharma Corporation (ABUS)
USD 3.19
(-7.8%)
USD 3.19
(-7.8%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -85.93 Million | -35.35 Million | -67.53 Million | -51.44 Million | -71 Million | -67.9 Million |
| Net Income | -72.84 Million | -69.45 Million | -76.24 Million | -63.74 Million | -153.72 Million | -57.1 Million |
| Depreciation & Amortization | 1.4 Million | 1.42 Million | 1.75 Million | 1.97 Million | 2.02 Million | 2.18 Million |
| Deferred income taxes | -10.7 Million | - | -8.17 Million | -5.59 Million | -12.66 Million | -4.28 Million |
| Stock-based compensation | 9.3 Million | 7.18 Million | 6.42 Million | 6.16 Million | 6.79 Million | 6.24 Million |
| Change in working capital | -18.23 Million | 29.24 Million | 930 Thousand | 431 Thousand | -2.22 Million | -4.27 Million |
| Other non-cash items | 5.14 Million | -3.75 Million | 7.78 Million | 9.32 Million | 88.77 Million | -10.66 Million |
| Investing Cash Flow | 50.77 Million | -74.94 Million | -12.67 Million | -14.9 Million | 28.33 Million | -4.1 Million |
| Investments in PPE | -1 Million | -512 Thousand | -809 Thousand | -229 Thousand | -589 Thousand | -1.13 Million |
| Acquisitions | 20 Thousand | 458 Thousand | 1.8 Million | -2.5 Million | 11 Thousand | 25 Thousand |
| Investment purchases | -80.5 Million | -130.43 Million | -82.21 Million | -85.57 Million | -58.75 Million | -3.01 Million |
| Sales/Maturities of investments | 132.27 Million | 56 Million | 70.35 Million | 73.39 Million | 87.67 Million | - |
| Other Investing Activities | 51.78 Million | -458 Thousand | -1.8 Million | -12.18 Million | 28.92 Million | -2.96 Million |
| Financing Cash Flow | 30.64 Million | 31.81 Million | 137.23 Million | 86.74 Million | 37.45 Million | 55.6 Million |
| Debt repayment | - | - | - | - | - | -12 Million |
| Dividends payments | - | - | -12.13 Million | -12.12 Million | -11.14 Million | -10.09 Million |
| Common Stock Repurchased | - | 10.97 Million | - | - | - | - |
| Common Stock Issuance | 30.64 Million | 31.81 Million | 134.66 Million | 86.29 Million | 18.6 Million | 67.64 Million |
| Other Financing Activities | 30.64 Million | 31.81 Million | 14.71 Million | 12.57 Million | 30 Million | 77.69 Million |
| Accounts receivables | -424 Thousand | -453 Thousand | 413 Thousand | -108 Thousand | 227 Thousand | -1.02 Million |
| Accounts payables | -5.75 Million | 5.21 Million | 1.91 Million | 1.66 Million | -2.41 Million | -1.26 Million |
| Inventory | 6.18 Million | - | -1.91 Million | - | - | 762 Thousand |
| Other working capital | -18.23 Million | 24.48 Million | 517 Thousand | -1.12 Million | -42 Thousand | -2.74 Million |
| Cash at beginning of period | 30.77 Million | 109.28 Million | 52.25 Million | 31.79 Million | 36.94 Million | 54.3 Million |
| Cash at end of period | 26.28 Million | 30.77 Million | 109.28 Million | 52.25 Million | 31.79 Million | 36.9 Million |
| Capital Expenditure | -1 Million | -512 Thousand | -809 Thousand | -229 Thousand | -589 Thousand | -1.13 Million |
| Effect of forex changes on cash | 25 Thousand | -22 Thousand | 5000.00 | 56 Thousand | 68 Thousand | -1 Million |
| Net cash flow / Change in cash | -4.49 Million | -78.5 Million | 57.03 Million | 20.45 Million | -5.14 Million | -17.4 Million |
| Free Cash Flow | -86.94 Million | -35.86 Million | -68.34 Million | -51.67 Million | -71.59 Million | -69.03 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -19.79 Million | -17.87 Million | -19.31 Million | -72.84 Million | -20.1 Million | -17.09 Million |
| Depreciation & Amortization | 356 Thousand | 355 Thousand | 359 Thousand | 1.4 Million | 369 Thousand | 342 Thousand |
| Deferred income taxes | - | - | -1.49 Million | -10.7 Million | -678 Thousand | -534 Thousand |
| Stock-based compensation | 3.18 Million | 2.01 Million | 1.72 Million | 9.3 Million | 2.48 Million | 2.96 Million |
| Change in working capital | 2.75 Million | -2.85 Million | 1.73 Million | -18.23 Million | -3.38 Million | -4 Million |
| Other non-cash items | -98.54 Thousand | 4.18 Million | 764.86 Thousand | 5.14 Million | -472 Thousand | -1.23 Million |
| Investing Cash Flow | 9.67 Million | 11.69 Million | 21.64 Million | 50.77 Million | 10.42 Million | 1.44 Million |
| Investments in PPE | -320.63 | -95 Thousand | 13.36 Thousand | -1 Million | -32 Thousand | -859 Thousand |
| Acquisitions | - | 37.18 Million | -265.10 | 20 Thousand | 20.08 Thousand | -2.3 Million |
| Investment purchases | -32.17 Million | -25.39 Million | -23.05 Million | -80.5 Million | -7.08 Million | -29.2 Million |
| Sales/Maturities of investments | 41.85 Million | 37.18 Million | 44.68 Million | 132.27 Million | 17.52 Million | 31.5 Million |
| Other Investing Activities | 9.73 Million | 458 Thousand | 1.10 | 51.78 Million | -84.00 | 2.3 Million |
| Financing Cash Flow | 24.02 Million | 24.43 Million | 3.41 Million | 30.64 Million | 1.68 Million | 4.74 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 24.02 Million | 24.43 Million | 3.41 Million | 30.64 Million | 1.39 Million | 4.74 Million |
| Other Financing Activities | 24.37 Million | 24.43 Million | 3.8 Million | 30.64 Million | 285 Thousand | 4.74 Million |
| Accounts receivables | 371.93 Thousand | -363 Thousand | 402.28 Thousand | -424 Thousand | 443 Thousand | 50 Thousand |
| Accounts payables | 2.85 Million | -2.02 Million | 543.27 Thousand | -5.75 Million | 1 Million | -848 Thousand |
| Inventory | - | - | 2.00 | 6.18 Million | -1 Million | -182 Thousand |
| Other working capital | -468.29 Thousand | -472 Thousand | 789.37 Thousand | -18.23 Million | -3.82 Million | -3.02 Million |
| Cash at beginning of period | 43.1 Million | 26.28 Million | 17.53 Million | 30.77 Million | 27.19 Million | 40.57 Million |
| Cash at end of period | 62.78 Million | 43.1 Million | 26.28 Million | 26.28 Million | 17.53 Million | 27.19 Million |
| Capital Expenditure | -320.63 | -95 Thousand | 13.36 Thousand | -1 Million | -32 Thousand | -859 Thousand |
| Effect of forex changes on cash | -8000.00 | -13 Thousand | 14 Thousand | 25 Thousand | 8000.00 | -1000.00 |
| Net cash flow / Change in cash | 19.68 Million | 16.81 Million | 8.75 Million | -4.49 Million | -9.66 Million | -13.37 Million |
| Free Cash Flow | -14.26 Million | -19.39 Million | -16.21 Million | -86.94 Million | -21.81 Million | -20.41 Million |
C1V
300150
GROWINGTON
DIOS
KNOS
8194